Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, has closed on an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of $6.50 per share, with gross proceeds of $65 million.
Stuart Falber led the WilmerHale team representing Tetraphase in this transaction, with a team that included Chris Barnstable-Brown, Emily Gainor and Tim Kulis.
Visit www.tetraphase.com for more information.